StockNews.com initiated coverage on shares of SCYNEXIS (NASDAQ:SCYX – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the stock.
Separately, Guggenheim assumed coverage on shares of SCYNEXIS in a research note on Tuesday, February 28th. They issued a buy rating and a $8.00 price target for the company.
SCYNEXIS Stock Down 10.2 %
Shares of NASDAQ SCYX opened at $1.15 on Thursday. The company has a debt-to-equity ratio of 2.63, a quick ratio of 7.21 and a current ratio of 7.26. SCYNEXIS has a 12 month low of $1.15 and a 12 month high of $5.15. The firm has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $2.03.
Institutional Inflows and Outflows
SCYNEXIS Company Profile
SCYNEXIS, Inc is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
- Get a free copy of the StockNews.com research report on SCYNEXIS (SCYX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.